SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million.

加利福尼亚州圣克拉拉（商业新闻短讯）--安捷伦科技有限公司（纽约证券交易所：A）今天宣布，它已经签署了一项最终协议，以9.25亿美元收购领先的专业合同开发和制造组织BIOVECTRA。

Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.

总部位于加拿大的BIOVECTRA生产生物制剂、高效活性药物成分和其他用于靶向治疗的分子。

The acquisition builds on Agilent’s CDMO specialization in oligonucleotides and CRISPR therapeutics in three key areas:

此次收购建立在安捷伦在寡核苷酸和CRISPR治疗方面的CDMO专业化基础上，涉及三个关键领域：

Expands portfolio of services. BIOVECTRA offers sterile fill-finish services, pDNA and mRNA capabilities, and lipid nanoparticle (LNP) formulation.

扩展服务组合。BIOVECTRA提供无菌灌装服务，pDNA和mRNA功能以及脂质纳米颗粒（LNP）配方。

Adds rapidly growing modalities. BIOVECTRA brings expertise in fast-growing segments, including antibody drug conjugates (ADCs), highly potent active pharmaceutical ingredients (HPAPIs), and GLP-1.

增加了快速增长的模式。BIOVECTRA在快速增长的领域带来了专业知识，包括抗体-药物偶联物（ADC），高效活性药物成分（HPAPI）和GLP-1。

Brings world-class capabilities to support gene editing. BIOVECTRA’s capabilities in biologics combined with Agilent’s expertise in gRNA will provide customers with a single source for gene-editing technology.

带来世界一流的功能来支持基因编辑。。

“We look forward to welcoming BIOVECTRA to Agilent,” said Agilent President and CEO Padraig McDonnell. “The company has an outstanding record of innovation, and its employees share our commitment to providing integrated biopharma solutions that continuously deliver more value to customers.”

安捷伦总裁兼首席执行官PadraigMcDonnell表示：“我们期待着欢迎BIOVECTRA加入安捷伦。”。“该公司拥有杰出的创新记录，其员工与我们一样致力于提供集成的生物制药解决方案，不断为客户提供更多价值。”

McDonnell continued: “Plus, BIOVECTRA’s manufacturing capabilities further expand Agilent’s end-to-end biopharma offerings into new growth vectors, including workflows that seamlessly integrate analytical instrumentation, consumables, and a wide range of lab services.”

McDonnell继续说道：“此外，BIOVECTRA的制造能力进一步将安捷伦的端到端生物制药产品扩展到新的增长载体，包括无缝集成分析仪器、耗材和各种实验室服务的工作流程。”

BIOVECTRA supports early-stage clinical development to large-scale commercial manufacturing. The company currently serves biotech and pharmaceutical companies in North America and Europe.

BIOVECTRA支持从早期临床开发到大规模商业制造。该公司目前为北美和欧洲的生物技术和制药公司提供服务。

“BIOVECTRA is excited to join Agilent, a company whose dedication to people and customers is very much aligned with ours,” said Oliver Technow, CEO of BIOVECTRA. “BIOVECTRA has dedicated nearly 55 years to the relentless pursuit of helping our customers solve complex problems that improve patients’ lives.

BIOVECTRA首席执行官Oliver Technow表示：“BIOVECTRA很高兴加入安捷伦，这家公司对员工和客户的奉献精神与我们的非常一致。”。“BIOVECTRA用了近55年的时间，坚持不懈地帮助我们的客户解决改善患者生活的复杂问题。

This synergistic pairing of our capabilities with Agilent’s will further enhance the value we can offer to our customers.”.

我们的能力与安捷伦的协同配合将进一步提高我们可以为客户提供的价值。”

BIOVECTRA delivered $113 million in revenue during 2023 and expects double-digit revenue growth in 2024. Agilent expects that the acquisition will be $0.05 dilutive to non-GAAP EPS in the first full year after closing. Agilent will fund the transaction using a mix of cash on hand and debt financing..

BIOVECTRA在2023年实现收入1.13亿美元，预计2024年收入将实现两位数增长。安捷伦预计，此次收购将在交割后的第一个完整年份以0.05美元的价格稀释非GAAP每股收益。安捷伦将使用库存现金和债务融资的组合为交易提供资金。

The transaction is subject to customary closing conditions, including receipt of regulatory approvals, and is expected to close before 2025. Upon close, BIOVECTRA will become part of the Agilent Diagnostics and Genomics Group.

该交易受惯例成交条件的约束，包括收到监管部门的批准，预计将在2025年之前完成。关闭后，BIOVECTRA将成为安捷伦诊断和基因组学集团的一部分。

About BIOVECTRA

关于BIOVECTRA

BIOVECTRA (www.biovectra.com) is a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial scale production capabilities for biologics, small molecules, bioreagents, lipids, pDNA, mRNA and LNP manufacturing and fill finish for drug products.

BIOVECTRA（www.BIOVECTRA.com）是一家全球生物技术和制药CDMO（合同开发和制造组织），专门从事生物制剂，小分子，生物制剂，脂质，pDNA，mRNA和LNP制造的临床至商业规模生产能力以及药品的填充饰面。

Flexibility, creativity, process optimization and compliance are at the heart of our method. With nearly 55 years of experience and cGMP facilities in Prince Edward Island and Nova Scotia, Canada, we assure our programs advance on time and with the highest quality outcomes..

灵活性、创造性、流程优化和合规性是我们方法的核心。凭借近55年的经验和在加拿大爱德华王子岛和新斯科舍省的cGMP设施，我们确保我们的计划按时推进，并取得最高质量的成果。

About Agilent Technologies

关于安捷伦科技

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions.

安捷伦科技有限公司（纽约证券交易所代码：A）是分析和临床实验室技术的全球领导者，提供见解和创新，帮助我们的客户将伟大的科学带入生活。安捷伦的全套解决方案包括仪器、软件、服务和专业知识，为客户最具挑战性的问题提供可靠的答案。

The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook..

2023财年，该公司实现收入68.3亿美元，在全球拥有约18000名员工。。在LinkedIn和Facebook上关注安捷伦。

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, statements regarding the capabilities the acquisition brings and the assets’ future uses.

本新闻稿包含《1934年证券交易法》中定义的前瞻性声明，并受其中创建的安全港的约束。本文包含的前瞻性陈述包括但不限于有关收购带来的能力和资产未来用途的陈述。

These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of Agilent’s customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; unforeseen changes in the currency markets; customer purchasing decisions and timing; and the risk that Agilent is not able to realize the savings expected from integration and restructuring activities.

这些前瞻性陈述涉及风险和不确定性，可能导致安捷伦的业绩与管理层目前的预期存在重大差异。此类风险和不确定性包括但不限于安捷伦客户业务实力的不可预见变化；当前和新产品、技术和服务需求的不可预见变化；货币市场不可预见的变化；客户购买决策和时间安排；以及安捷伦无法实现整合和重组活动预期节省的风险。

In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that its cost-cutting initiatives will impair its ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on its operations, its markets and its ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of its supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agil.

此外，安捷伦在运营中面临的其他风险包括在商业周期中成功执行的能力；能够满足并实现其成本降低目标的好处，并成功地使其成本结构适应业务条件的持续变化；持续的竞争、定价和毛利率压力；其成本削减举措可能会削弱其开发产品、保持竞争力和有效运营的能力；地缘政治不确定性和全球经济状况对其运营、市场和经营能力的影响；改进资产绩效以适应需求变化的能力；其供应链适应需求变化的能力；能够在正确的时间、价格和组合成功推出新产品；敏捷的能力。